HCW Biologics (NASDAQ:HCWB) Stock Bumped Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of HCW Biologics (NASDAQ:HCWB) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Stock Performance

Shares of HCWB opened at $1.10 on Friday. The stock has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $4.16. The stock has a market capitalization of $2.46 million, a PE ratio of -0.04 and a beta of 2.41. HCW Biologics has a 1 year low of $1.09 and a 1 year high of $23.94.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%. The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.14 million.

About HCW Biologics

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.